Detection ofCoxiella burnetii by PCR in mice after administration of live M-44 vaccine

Mossienko, E. V.; Токаревич, Н. К.; Suvorov, Alexander; Тотолян, А.

doi:10.1007/bf02931284

Cited by 6 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A live attenuated vaccine was developed from the M-44 strain of C. burnetii to vaccinate Soviet volunteers (137)(138)(139). However, it was demonstrated that organisms persisted for a long time in inoculated animals, which is indicative of the potential for reactivation (140)(141)(142).…”

Section: Other Vaccine Strategiesmentioning

confidence: 99%

Vaccine-induced protective immunity against coxiella burnetii

Ledbetter¹

View full text Add to dashboard Cite

Coxiella burnetii is an obligate intracellular Gram-negative bacterial pathogen and the causative agent of human Q fever. This disease presents acutely as a flu-like illness, although it can escalate to a chronic and often fatal disease when left untreated. Considering no FDA-approved vaccine exists, the creation of a safe and effective vaccine remains an important public health goal. A formalin-inactivated C. burnetii Nine Mile strain phase I whole-cell vaccine generates protective immunity in a mouse model of experimental Q fever, although the mechanisms of protection remain unclear. Chapter 3 details my work establishing an early vaccine protection model and elucidating the cellular immune response which elicits early protection. The early time point at which PIV protects has implications for its use as a therapeutic vaccine. Furthermore, the innate-driven mechanisms by which it protects can be exploited for an improved Q fever vaccine. The importance of T cells in vaccine immunity against C. burnetii is well supported, however, multiple questions remain. It is unclear how CD4+ or CD8+ T cells contribute to vaccine protection, and the role of specific CD4+ T cell subsets is unknown. IFN-[theta] is critical for primary defense against C. burnetii, though its importance in vaccine immunity is undetermined. Chapter 4 describes my work aimed at filling these knowledge gaps. Vaccine development efforts have largely focused on the generation of antibodies as a correlate of protection. It has become clear that targeting T cells is more critical to vaccine protection and a better understanding of the mechanisms of cell-mediated immunity will inform future Q fever vaccine development.

show abstract

Section: Other Vaccine Strategiesmentioning

confidence: 99%

Vaccine-induced protective immunity against coxiella burnetii

Ledbetter¹

View full text Add to dashboard Cite

show abstract

Q fever

Parker¹,

Barralet²,

Bell³

2006

The Lancet

416

437

View full text Add to dashboard Cite

Q fever is a zoonosis with many manifestations. The most common clinical presentation is an influenza-like illness with varying degrees of pneumonia and hepatitis. Although acute disease is usually self-limiting, people do occasionally die from this condition. Endocarditis is the most frequent chronic presentation. Although Q fever is widespread, practitioner awareness and clinical manifestations vary from region to region. Geographically limited studies suggest that chronic fatigue syndrome and cardiovascular disease are long-term sequelae. An effective whole-cell vaccine is licensed in Australia. Live and acellular vaccines have also been studied, but are not currently licensed.

show abstract